Related Experiment Video
Updated: Aug 9, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Hormone Replacement Therapy in Postmenopausal Women: Does It Lessen Coronary Heart Disease Risk?
1Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA.
Insights
Coronary heart disease is a major threat for postmenopausal women. Research is exploring estrogen therapy
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Women's Health
Background:
- Coronary heart disease (CHD) is the primary cause of mortality in US adult women.
- Clinical CHD manifestations are most prevalent in postmenopausal women, highlighting the need to study hormone-estrogen interactions.
- Estrogen offers potential cardiovascular benefits, including improved lipid profiles and vascular function.
Purpose of the Study:
- To evaluate the relationship between coronary disease and gonadal hormones in postmenopausal women.
- To assess the benefit:risk ratio of estrogen and estrogen/progestin therapies for coronary disease prevention.
Main Methods:
- Review of existing literature on estrogen's effects on cardiovascular risk factors.
- Emphasis on the need for randomized clinical trial data due to limitations of observational studies.
- Ongoing clinical trials are investigating transdermal estrogen and combined hormone therapies.
Main Results:
- Observational studies suggest estrogen use may reduce coronary risk.
- Potential benefits include improved lipid profiles, reduced fibrinogen, and enhanced vascular reactivity.
- Data on the benefit:risk profiles of specific estrogen formulations (transdermal, combined) is currently limited.
Conclusions:
- Estrogen therapy warrants further investigation for coronary heart disease prevention in postmenopausal women.
- Randomized trials are crucial to confirm benefits and assess risks of different hormone therapies.
- More information is needed on the comparative efficacy and safety of various estrogen preparations.
Abstract:
Coronary heart disease is the leading cause of death in adult women in the U.S. Since clinical manifestations of coronary disease predominate in postmenopausal women, the need to evaluate coronary disease-gonadal hormone relationships is compelling. Further, estrogen exerts biologically plausible benefits: improved lipid profile, lower fibrinogen levels, favorable changes in vascular reactivity, possible antioxidant effects, among others. Although observational studies of estrogen use suggest substantial lessening of coronary risk, selection biases favoring a healthy cohort of women mandate randomized clinical trial data, with such trials currently in progress. Information is lacking regarding benefit: risk ratios of transdermal estrogen and estrogen/progestin combinations as coronary preventive therapies.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management
Heart Failure V: Medical Management
Atherosclerosis III: Management

